THU0691 Is serum amyloid a protein an useful biomarker to monitor treatment with anti-tumour necrosis factor-alpha agents in spondyloarthritis patients? | Annals of the Rheumatic Diseases

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

Podcasts
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article info

Poster Presentations

Validation of outcome measures and biomarkers

THU0691 Is serum amyloid a protein an useful biomarker to monitor treatment with anti-tumour necrosis factor-alpha agents in spondyloarthritis patients?

Free

Authors

F Aguiar Rheumatology, Centro Hospitalar São João, Oporto, Portugal PubMed articles Google scholar articles
D Rosa-Gonçalves Rheumatology, Centro Hospitalar São João, Oporto, Portugal PubMed articles Google scholar articles
T Martins-Rocha Rheumatology, Centro Hospitalar São João, Oporto, Portugal PubMed articles Google scholar articles
RM Ferreira Rheumatology, Centro Hospitalar São João, Oporto, Portugal PubMed articles Google scholar articles
A Bernardo Rheumatology, Centro Hospitalar São João, Oporto, Portugal PubMed articles Google scholar articles
I Brito Rheumatology, Centro Hospitalar São João, Oporto, Portugal PubMed articles Google scholar articles
M Bernardes Rheumatology, Centro Hospitalar São João, Oporto, Portugal PubMed articles Google scholar articles

Citation

Aguiar F, Rosa-Gonçalves D, Martins-Rocha T, et al

THU0691 Is serum amyloid a protein an useful biomarker to monitor treatment with anti-tumour necrosis factor-alpha agents in spondyloarthritis patients?

Annals of the Rheumatic Diseases 2017;76:468-469.

Publication history

First published June 15, 2017.

Online issue publication

January 09, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions